The Food and Drug Administration (FDA) on Friday gave green signal to the first set of glucose-monitoring medical applications that can assist sharing of data in real time, both automatically and securely.
The medical app, which is developed by California-based Dexcom Inc., carries a small, wire-like sensor that is inserted under the skin layer, which transmits data to an externally-worn monitor.
In a statement, Alberto Gutierrez, director of the FDA’s Office of In Vitro Diagnostics and Radiological Health, said, “This innovative technology has been eagerly awaited by the diabetes community, mainly caregivers of children with diabetes who want to monitor their glucose levels remotely.”
The system will allow the doctors and other medical professionals to track the blood-sugar levels of people with diabetes, which is often regarded as ‘sweet killer’, by logging into a smartphone app.
The new medical app serves as the latest example of how the growing mobile technologies have changed the health care landscape.
While using the smartphone app, the diabetics can designate their “followers” with whom they want to share their information. The app then receives real-time data and sends it to a W000-based storage location. The follower can download the information or simply view with the help of the app.
The green signal from the FDA for marketing purposes for the Dexcom’s new system could pave the path for various similar technologies. As the app has been approved by the FDA as a “low- to moderate-risk” medical device, other developers planning to launch a similar app in the future won’t require to get prior clearance from the agency. But they require to register their product with the federal agency.